MAY 25, 2020 3:27 PM PDT

Hydrochloroquine Increases Risk of Death by COVID-19

WRITTEN BY: Annie Lennon

Researchers have found that hydroxychloroquine is not an effective treatment for COVID-19. Their study found that it leads to a significantly higher risk of death when compared to other treatments. 

For the study, the researchers gathered data on 96,032 patients across six continents with COVID-19 between December 20th, 2019, and April 14th, 2020. They received variations of chloroquine, hydrochloroquine and macrlides (antibiotics such as azithromycin and clarithomycin) within 48 hours of diagnosis. The researchers excluded patients who received remdesivir, already shown to improve patient outcomes, ventilator treatment, and those who received treatment after 48 hours from diagnosis. 

After controlling their results for confounding factors such as age, sex, race, and ethnicity, the researchers found that those taking chloroquine regimens were more likely to die than those who did not. They also found that those patients on these regimens had an increased risk of ventricular arrhythmia, a condition that causes abnormal heartbeat and can result in sudden cardiac death. 

The researchers thus concluded that there is no evidence to suggest that chloroquine is effective against COVID-19. Eric Topol, a cardiologist and director of the Scripps Research Translational Institute, says, "It's one thing not to have benefit, but this shows distinct harm...If there was ever hope for this drug, this is the death of it."

The researchers say that their findings provide a fair indication of the drug's effectiveness due to the study's large sample size. However, as itis a retrospective analysis of medical records and not a controlled clinical study, they caution that their results may not be conclusive. 

As the results more or less echo results from smaller previous studies, however, Steven Nissen, a cardiologist at the Cleveland Clinic, said that the drug may be "harmful and that no one should be taking it outside of a clinical trial."


Sources: Washington Post, BBC, The Lancet

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 15, 2022
Drug Discovery & Development
Low-dose Lithium Has Anti-aging Effects on Liver
APR 15, 2022
Low-dose Lithium Has Anti-aging Effects on Liver
Low-dose lithium can block an enzyme linked to cellular aging and functional decline in the kidneys. The corresponding s ...
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
APR 25, 2022
Microbiology
How a Serious Infection Can Cause Mood Disorders
APR 25, 2022
How a Serious Infection Can Cause Mood Disorders
When a pathogen invades the body, the immune system has to mount a response, which involves inflammation. But inflammati ...
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
MAY 26, 2022
Drug Discovery & Development
Sonic Hedgehog gene speeds up large-scale bone regeneration
MAY 26, 2022
Sonic Hedgehog gene speeds up large-scale bone regeneration
Some species of lizards can detach their tails from their bodies when they feel threatened. This common defense mechanis ...
JUN 02, 2022
Drug Discovery & Development
NSAIDs Can Have Different, Unexpected Effects on People. Why?
JUN 02, 2022
NSAIDs Can Have Different, Unexpected Effects on People. Why?
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common types of drugs used to treat pain and inflammat ...
Loading Comments...